News Article | May 10, 2017
LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global caviar market to grow to USD 1.55 billion by 2021, at a CAGR of close to 12% over the forecast period, according to their latest report. The research study by Technavio on the global caviar market for 2017-2021 provides a detailed industry analysis based on the product (inorganic and organic caviar), distribution channel (supermarkets, independent retailers, online stores, and specialty stores), and geography (EMEA, the Americas, and APAC). EMEA is the leading segment of the global caviar market, projected to generate both the highest revenue and maximum incremental growth over the forecast period. The growing number of sturgeon farms in Europe and growing demand for caviar from Africa and the Middle East are expected to be responsible for the continued market dominance of the region over the forecast period. This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free. Technavio analysts highlight the following three factors that are contributing to the growth of the global caviar market: “There is a global increase in disposable income among consumers, which has led to an increase in demand for luxury goods such as caviar, mainly due to the rarity of these products,” says Manjunath Reddy, a lead analyst at Technavio for food research. Luxury food sales are growing around the globe and are expected to increase further during the forecast period, with food products holding a market share of about 13%-14% in the luxury goods market. Caviar's restricted availability and its resultant high price attract consumers who indulge in fine dining. Caviar is a rich source of Vitamin A, potassium, and omega-3. These components aid in repairing damaged skin cells, moisturizing, reducing blood pressure, and maintaining heart health. It is also recommended for patients undergoing chemotherapy; and said to help prevent Alzheimer’s disease. Additionally, the Vitamin B12 present in caviar is useful in reducing the severity of conditions such as insomnia, anxiety, and stress. These health benefits associated with the consumption of caviar is one of the key drivers impacting the consumption of caviar around the globe. “Various players in the caviar market have developed new, innovative methods of processing caviar, where the sturgeon are not killed. This not only helps in increasing the population of the endangered sturgeons but also paves the way for a more sustainable business model,” says Manjunath. The Alfred Wegener Institute in Germany developed a new method for processing, where the caviar was produced from eggs that were stripped from live female sturgeon without killing the fish. Under this process, the signaling molecules in very small natural concentrations activate a machinery of enzymes that stabilize the egg membranes within milliseconds. Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like food service, alcoholic beverages, and non-alcoholic beverages. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently. Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users. If you are interested in more information, please contact our media team at firstname.lastname@example.org.
News Article | May 22, 2017
Half of Americans age 50 and older have been the recipients of a monetary gift or family loan since becoming an adult. People with an inheritance are more than twice as likely as those without one to feel prepared for retirement (38 percent vs. 17 percent), according to a new survey of Americans age 50 or older from The Associated Press-NORC Center for Public Affairs Research. The survey also found that 56 percent think it is an adult child's responsibility to provide financial assistance to a parent if needed. At the same time, 46 percent say it is a parent's responsibility to provide financial assistance to an adult child if needed. Though Hispanics and African Americans are less likely than whites to benefit from family wealth, they are the most likely to provide financial assistance to parents or in-laws. "Naturally, people who report receiving help from family members have less anxiety when it comes to planning for retirement, but there is much more to these results," said Trevor Tompson, director of The AP-NORC Center. "Four in 10 anticipate that they will outlive their savings. As Americans continue to recover from the Great Recession, and with broader income inequality on the rise, saving and preparing for retirement will not get any easier for future generations as many are unlikely to be able to rely on inheritances from their parents." The 2017 study, funded by the Alfred P. Sloan Foundation, is a continuation and expansion of the 2013 and 2016 surveys from The AP-NORC Center. The 2017 study extends the previous research and examines new topics, including older workers' experiences with intergenerational wealth transfers, unemployment and saving for retirement, and how experiences with the penal system affect the retirement planning of older Americans. The survey also tracks a number of attitudes and behaviors that were examined in 2013 and 2016 surrounding issues facing older workers. This survey, funded by The Alfred P. Sloan Foundation, was conducted by The Associated Press-NORC Center for Public Affairs Research between the dates of February 14 and March 13, 2017. Staff from NORC at the University of Chicago, The Associated Press, and The Alfred P. Sloan Foundation collaborated on all aspects of the study. This work is part of The AP-NORC Center for Public Affairs Research Journalism Fellowship on the Economics of Aging and Work. The current fellow is journalist Maria Zamudio. Panel members were randomly drawn from AmeriSpeak, and 1,683 completed the survey--1,049 via the web and 634 via telephone. The sample also included 332 African Americans and 308 Hispanics. For purposes of analysis, African-American and Hispanic respondents were oversampled in this poll and then weighted back to their proper proportion according to the U.S. Census. Interviews were conducted in both English and Spanish, depending on respondent preference. The overall margin of sampling error is +/- 3.0 percentage points at the 95 percent confidence level, including the design effect. Among subgroups, the margin of sampling error at the 95 percent confidence level is +/- 3.5 percentage points for African Americans and +/- 4.6 percentage points for Hispanics. The AP-NORC Center for Public Affairs Research taps into the power of social science research and the highest-quality journalism to bring key information to people across the nation and throughout the world. http://www. The Associated Press (AP) is the essential global news network, delivering fast, unbiased news from every corner of the world to all media platforms and formats. Founded in 1846, AP today is the most trusted source of independent news and information. On any given day, more than half the world's population sees news from AP. http://www. NORC at the University of Chicago is an independent research institution that delivers reliable data and rigorous analysis to guide critical programmatic, business, and policy decisions. Since 1941, NORC has conducted groundbreaking studies, created and applied innovative methods and tools, and advanced principles of scientific integrity and collaboration. Today, government, corporate, and nonprofit clients around the world partner with NORC to transform increasingly complex information into useful knowledge. http://www. The two organizations have established The AP-NORC Center for Public Affairs Research to conduct, analyze, and distribute social science research in the public interest on newsworthy topics, and to use the power of journalism to tell the stories that research reveals. Contact: For more information, contact Eric Young for NORC at email@example.com or (703) 217-6814 (cell); Ray Boyer for NORC at firstname.lastname@example.org or (312) 330-6433; or Lauren Easton for AP at email@example.com.
News Article | April 18, 2017
IRVINE, Kalifornien (USA)--(BUSINESS WIRE)--Axonics Modulation Technologies Inc., Entwickler des ersten wiederaufladbaren Sakral-Neuromodulationssystems (r-SNM™) für die Behandlung von Harn- und Stuhlinkontinenz, hat heute angekündigt, dass erste Ergebnisse seiner prospektiven klinischen Multizentrumsstudie erstmals auf dem Weltkongress der International Neuromodulation Society (INS) am 30. Mai 2017 in Edinburgh, Schottland, präsentiert werden sollen. „Das Axonics-r-SNM System wurde von den Patienten, von den beteiligten Forschern und vom klinischen Personal äußerst gut angenommen“, sagte Raymond W. Cohen, Chief Executive Officer von Axonics. „Die Studie, mit der die Sicherheit und Wirksamkeit des Produkts bestätigt werden sollte, übertraf ihre Zielsetzung sogar. Der Schwerpunkt unserer Arbeit liegt jetzt mehr darauf, eine Pivotalstudie in den USA durchzuführen und die Zulassung der FDA zu erhalten. In der Zwischenzeit freuen wir uns jedoch darauf, unser Produkt für Patienten in ausgewählten internationalen Zentren verfügbar zu machen.“ Das Axonics r-SNM System hat im Juni 2016 die europäische CE-Kennzeichnung und im Dezember 2016 die Zulassung von Health Canada für die Behandlung von Blasenhyperaktivität, Harnretention und Stuhlinkontinenz erhalten. Von diesen Erkrankungen sind in den USA und Europa über 100 Millionen Erwachsene betroffen. SNM ist eine erstattungsfähige und von der FDA zugelassene Therapie, die sich als wirksame, dauerhafte Behandlung bewährt und in Europa und in den USA in den letzten zwei Jahrzehnten mehr als 250.0000 Patienten geholfen hat. Axonics hat vor, in der zweiten Jahreshälfte 2017 eine US-FDA klinische Pivotalstudie für hyperaktive Blasenpatienten in ausgewählten Zentren in den USA, Kanada und Europa zu starten. Über Axonics Modulation Technologies Inc. Axonics mit Firmensitz in Irvine, Kalifornien ist ein wagniskapitalfinanziertes Unternehmen in Privatbesitz, das eine neuartige, implantierbare Neuromodulationstechnologie für Patienten mit Harn- und Stuhlinkontinenz entwickelt hat, die auch für mehrere weitere klinische Indikationen genutzt werden kann. Das Axonics r-SNM System besteht aus einem aufladbaren Mini-Stimulator, der mindestens 15 Jahre funktionieren wird, einem für reduzierte Ladezeit und minimale Erhitzung optimierten Ladesystem, einer patientenfreundlichen Fernsteuerung und einem intuitiven Programmierer für den Kliniker, die die Elektrodenplatzierung und Programmierung der Leitung erleichtert. Die Investoren sind Edmond de Rothschild Investment Partners, Advent Life Sciences, NeoMed Management, Legend Capital, Cormorant Asset Management und The Alfred E. Mann Foundation. Weitere Informationen finden Sie auf der Unternehmens-Website unter www.axonicsmodulation.com.
News Article | July 11, 2017
Human presence in closed habitats that may one day be used to explore other planets is associated with changes in the composition of the fungal community - the mycobiome - that grows on surfaces inside the habitat, according to a study published in the open access journal Microbiome. Dr Kasthuri Venkateswaran, Senior Research Scientist at the NASA Jet Propulsion Laboratory, Caltech, and corresponding author of the study said: "Our study is the first report on the mycobiome of a simulated habitat meant for the future human habitation of other planets. We used the Inflatable Lunar/Mars Analog Habitat (ILMAH), a unique, simulated closed environment that mimics the conditions found on the International Space Station and possible human habitats on other planets. We showed that the overall fungal diversity changed when humans were present." The researchers found that certain kinds of fungi - including known pathogens that can colonize the human body and cause allergies, asthma and skin infections - increased in number while humans were living inside the ILMAH. Prolonged stays in closed habitats might be stressful for inhabitants and thus lead to decreased immune response, making people more vulnerable to opportunistic pathogens like fungi. Dr Venkateswaran said: "Fungi are extremophiles that can survive harsh conditions and environments like deserts, caves or nuclear accident sites, and they are known to be difficult to eradicate from other environments including indoor and closed spaces. Characterizing and understanding possible changes to, and survival of, fungal species in environments like the ILMAH is of high importance since fungi are not only potentially hazardous to the inhabitants but could also deteriorate the habitats themselves." Knowing how fungal communities change in the presence of humans is thus necessary for the development of appropriate countermeasures to maintain habitats like the ILMAH or the ISS and to protect the health of the people who live there. The primary goal of the ILMAH was to understand the physiological, psychological, and behavioral changes in humans in a confined environment. Three student crews were housed inside the ILMAH for 30 days. In order to determine which fungal species were present and how the composition of the mycobiome changed during human habitation, samples collected at various time points in a 30-day period were characterized. The ILMHA was completely isolated from the outside world, except for the exchange of filtered air between the indoor and outdoor environments. Crew members were given a weekly work schedule which included cleaning the habitat and collecting surface samples. Samples were collected from eight sampling locations at four time-points; just before habitation and at 13, 20 and 30 days of habitation. The habitat was cleaned weekly with antibacterial wipes. The researchers gene sequenced the samples to show which species of fungus were present and to determine the total (alive and dead) and viable (alive and able to reproduce) fungal populations. They showed that the diversity of the mycobiome and the levels of different fungal populations changed during the duration of the experiment. For example, populations of Cladosporium cladosporioides - a common outdoor fungus - increased. While C. cladosporioides rarely causes infections in humans, it could cause asthmatic reactions especially in individuals with weakened immune systems, such as astronauts. Dr Venkateswaran said: "In-depth knowledge of the viable mycobiome will allow the development of required maintenance and cleaning procedures in a closed habitat like ILMAH and also prevent it from deteriorating and becoming a health hazards to its inhabitants. However, to be able to show that increased fungal diversity is a result of human presence, the mycobiome of the occupants will also need to be studied." 1. An image is available here: http://bit. - appropriate credit must be given in any re-use. Caption and credit information is in the filename. An embargoed copy of the research article is available from Anne Korn at BioMed Central (firstname.lastname@example.org) After the embargo lifts, the article will be available at the journal website here: https:/ Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy. 3. The central purpose of Microbiome is to unite investigators conducting microbiome research in environmental, agricultural, and biomedical arenas. Topics broadly addressing the study of microbial communities, such as, microbial surveys, bioinformatics, meta-omics approaches and community/host interaction modeling will be considered for publication. Through this collection of literature Microbiome hopes to integrate researchers with common scientific objectives across a broad cross-section of sub-disciplines within microbial ecology. 4. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Nature, a major new force in scientific, scholarly, professional and educational publishing, created in May 2015 through the combination of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media. http://www. 5. The research article is part of the 'Microbiome of the Built Environment (MoBE) 2017: Research to Application' series which presents the latest MoBE research findings furthering our understanding of the formation and function of microbial communities in built environments, their impacts on human health, and how human occupants shape complex indoor microbiomes in relation to human exposure. The Alfred P. Sloan Foundation and The National Academies of Sciences, Engineering and Medicine are co-hosting the Microbiology of the Built Environment Research and Applications Symposium (MoBE 2017) from 10th to 12th October.
News Article | February 28, 2017
BELLEVUE, WA--(Marketwired - February 28, 2017) - Today, corporate wellness technology company Limeade announced two speakers headlining Limeade Engage -- a conference for HR leaders to transform employee engagement and rethink the way we work. Keynote speakers include Diana Nyad, record-breaking athlete, inspirational speaker and author of "Find A Way" and Dr. Barry Schwartz, popular TED speaker and author of "Why We Work." The event will take place in Seattle on May 2-3rd, 2017. "Work doesn't have to be draining. In fact, it can bring meaning and joy into our lives. As HR leaders we should feel empowered to drive this transformation at our organizations," said Steven Parker, vice president of customer success at Limeade and former HR executive. "Diana's incredible story and Barry's research will help Limeade Engage attendees discover that purpose is a critical dimension of well-being, and that a fulfilled workforce drives better business results." Accomplished Speakers Diana Nyad is a record-breaking athlete, author and inspirational speaker. At the age of sixty-four, she became the first person to swim from Cuba to Florida without the aid of a shark cage, swimming 111 miles in fifty-three hours from Havana to Key West. Her world records, circling Manhattan Island and crossing the 102.5 miles between the Bahamas and Florida, led to inductions into many Halls of Fame, including the International Women's Sports Hall of Fame. Nyad is a uniquely passionate speaker who wrote three books and became a prominent sports broadcaster, filing compelling reports for NPR, ABC's Wide World of Sports, Fox Sports, and The New York Times. Dr. Barry Schwartz is the author of more than 10 books including, "The Paradox of Choice" (2005) and "Why We Work" (2015), an eye-opening, groundbreaking tour of the purpose of work in our lives. With grant support from the National Science Foundation, The Alfred P. Sloan Foundation, and the MacArthur Foundation, Schwartz published more than 100 journal articles. Schwartz is a professor of psychology at Swarthmore College, and a fellow of both the American Psychological Association and the Association for Psychological Science. "Dr. Schwartz will reveal how to find meaning in ordinary work, and Diana will inspire us to find it in the extraordinary," said Parker. "HR leaders will leave Limeade Engage inspired and prepared to apply these insights to their work." For more information on Limeade Engage, event details and registration, please visit www.limeade.com/engage or join the conversation on Twitter using #LimeadeEngage. About Limeade Limeade is a corporate wellness technology company that drives real employee engagement. Limeade takes a whole-person approach to well-being, amplifies an organization's commitment to its employees and delivers smart technology that fits how people work today. Employees earn points and rewards for taking steps to improve, while employers experience better business results. Recognized for its own award-winning culture, Limeade helps the world's best companies develop happier, healthier and more productive employees. Learn more at www.limeade.com.
News Article | February 23, 2017
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics four new U.S. patents relating to its implantable sacral neuromodulation technology. “The diverse and rapid expansion of the Axonics U.S. patent portfolio further demonstrates the level of innovation applied by our Company in addressing the unmet needs of clinicians and patients relating to implantable Sacral Neuromodulation. With these four new U.S. patents, we now have 73 granted and 78 pending patent applications in our portfolio in various jurisdictions around the world,” said Raymond W. Cohen, Axonics Chief Executive Officer. The Axonics patent portfolio represents technology internally developed by Axonics and under license from the Alfred Mann Foundation. The Axonics r-SNM System® received European CE Mark approval in June 2016 and Health Canada approval in December 2016 for the treatment of overactive bladder (including urinary urge incontinence and urinary urgency-frequency), urinary retention, and fecal incontinence. The Company has completed enrollment of its RELAX-OAB multi-center post-market clinical study for patients with overactive bladder in select centers in the Netherlands, Belgium, France and the UK. Axonics anticipates initiating a U.S. FDA pivotal clinical study for overactive bladder patients in select centers in the U.S., Canada and Europe in the second half of 2017. The Axonics neuromodulation platform includes, among other innovations, a miniaturized rechargeable implantable neuromodulation stimulator that is approximately one-fourth the size of the smallest currently marketed rechargeable neuromodulation devices and can be directed toward numerous clinical applications. The Axonics stimulator is qualified to last at least 15 years in the body and needs to be recharged once every week or two for approximately one hour via a charging system designed to optimize ease of use and patient comfort. In addition, the Axonics platform features a key-fob sized, patient-friendly remote control and an intuitive clinician programmer that will guide and support physician implanters throughout the clinical procedure, from lead placement to programming. Axonics’ initial clinical application for its technology is Sacral Neuromodulation (SNM) for the treatment of urinary and fecal dysfunction which affects over 100 million adults in the U.S. and Europe. SNM is a reimbursed FDA-approved therapy that has proven to be an effective and durable treatment widely used in Europe and the U.S. for the past two decades with more than 200,000 patients having benefited from the therapy to date. Axonics, based in Irvine, CA, is a privately-held company developing novel implantable neuromodulation technology directed toward a number of clinical indications. Investors include Edmond de Rothschild Investment Partners, Advent Life Sciences, NeoMed Management, Legend Capital, Cormorant Asset Management and The Alfred E. Mann Foundation. For more information, visit the Company’s website at www.axonicsmodulation.com.
News Article | February 21, 2017
NEW YORK, Feb. 21, 2017 /PRNewswire-USNewswire/ -- The Alfred P. Sloan Foundation announces the selection of 126 outstanding U.S. and Canadian researchers as the recipients of the 2017 Sloan Research Fellowships. The fellowships, awarded yearly since 1955, honor those early-career...
News Article | February 21, 2017
Sebastian Will, an assistant professor in the Department of Physics at Columbia University, has been named a 2017 Sloan Research Fellow. An assistant professor at Columbia since 2016, Will's research interests include ultracold molecules and dipolar quantum gases, quantum simulation and quantum magnetism, and ultracold Fermi gases and Bose-Einstein condensates. It sounds complicated, but Will explained that this area of research is important because it allows for a fundamental understanding about quantum many-body systems. "Simply put," he said, "we're investigating how nature gives order to systems that consist of many interacting particles. In every-day life we see what nature does in basic ways -- stuff can be a solid, a liquid, or a gas - those are the three basic states of matter. However, in the world of quantum mechanics, many more states of matter are possible. One of them is the state of a superconductor - electricity can flow without any resistance, which means no power is lost. With ultracold atoms and molecules we try to understand such quantum states of matter better. This may allow us to design new materials with powerful and technologically relevant properties. Personally, I am most excited that we can observe states of matter in the lab that no one has ever observed before. Who knows what they will be useful for in the future? That's the beauty of fundamental research." The Alfred P. Sloan Foundation awards two-year, $60,000 fellowships to 126 researchers from the United States and Canada annually. The fellowships, awarded since 1955, recognize the distinguished performance of early-career scholars and their unique potential to make substantial contributions to their field. Administered and funded by the foundation, the fellowships are awarded in eight scientific fields: chemistry, computer science, economics, mathematics, evolutionary and computational molecular biology, neuroscience, ocean sciences, and physics. To qualify, candidates must first be nominated by fellow scientists and subsequently selected by an independent panel of senior scholars. "Getting early-career support can be a make-or-break moment for a young scholar," said Paul L. Joskow, president of the Alfred P. Sloan Foundation, in a press release. "In an increasingly competitive academic environment, it can be difficult to stand out, even when your work is first rate. The Sloan Research Fellowships have become an unmistakable marker of quality among researchers. Fellows represent the best-of-the-best among young scientists." "It is a great honor to be selected," Will said. "The Sloan Research Fellowship has an enormous tradition. Among the awardees are some of the greatest physicists, such as Richard Feynman. It is quite amazing to stand on the shoulders of such giants." He added that the money will be used for experiments that deepen the exploration of ultracold molecules. "It will hopefully help to uncover more miracles of the quantum world," he said. Since the beginning of the program, 43 Sloan Fellows have earned Nobel Prizes, 16 have won the Fields Medal in mathematics, 69 have received the National Medal of Science, and 16 have won the John Bates Clark Medal in economics. Other 2017 Sloan Research Fellows include a chemist developing a heat-reflective window paint to help reduce air conditioning demands in hot climates; an evolutionary biologist who models how human gene distributions change with migration; an astronomer using state-of-the-art spectroscopy to study the galaxy's most massive stars; a computer scientist whose work upended a 25-year consensus on algorithmic efficiency; an ocean scientist studying how marine organisms adapt to climate change and the costs of those adaptations; an economist who examines the ways that racial bias among managers can suppress employee productivity; a mathematician developing optimal methods for the efficient analysis of large datasets; and a neuroscientist who studies the way bats learn through echolocation as a model for understanding language development. To learn more about Professor Will's research, visit: http://www.
News Article | February 22, 2017
Two UC Santa Barbara faculty members -- cryptographer Stefano Tessaro and condensed matter physicist Andrea Young -- have been selected to receive research fellowships from the Alfred P. Sloan Foundation for 2017. The fellowships, awarded yearly since 1955, honor those early-career scholars whose achievements mark them as the next generation of scientific leaders. "Stefano Tessaro, who won an NSF CAREER award last year, is providing a deeper and more rigorous understanding of encryption for cyber security," said Joe Incandela, UCSB interim vice chancellor for research. "Andrea Young has won many awards recently, including one from the Packard Foundation for cutting-edge breakthroughs related to the creation of new states of matter with the potential for extraordinary technological advances -- most notably in ultra-thin graphene samples. We are extremely pleased to have such outstanding young researchers on our campus." Tessaro and Young will each receive a $60,000 fellowship to be used as they wish to further their research. "I am honored and thrilled to have been selected," said Tessaro, whose work focuses on ensuring the security of the encryption algorithms we use every day to send our private information over the internet. "Cryptography has become of paramount importance and its deployment has been growing steadily over the last few years," he added. "The fellowship will support my research efforts in building solid theoretical foundations that support the development of cryptographic methods. The hope is that the answers resulting from this work will play a significant role in securing our digital infrastructure." Andrea Young, meanwhile, develops and investigates the properties of new materials whose behavior reflects the rules of quantum mechanics even on macroscopic scales. "I'm very grateful to Sloan for the recognition," Young said. "Pushing the limits of what we understand about interacting quantum particles is essential for developing electronic devices for the long-term future, and it is far-sighted to invest in a field that can both expand our understanding of basic physics and ultimately yield new functionality for electronic hardware." Past Sloan Research Fellows include many towering scientific figures, including physicists Richard Feynman and Murray Gell-Mann, and game theorist John Nash. Forty-three former fellows have received a Nobel Prize in their respective field, 16 have won the Fields Medal in mathematics, 69 have received the National Medal of Science, and 16 have won the John Bates Clark Medal in economics, including every winner since 2007. "The Sloan Research Fellows are the rising stars of the academic community," said Paul L. Joskow, president of the Alfred P. Sloan Foundation. "Through their achievements and ambition, these young scholars are transforming their fields and opening up entirely new research horizons. We are proud to support them at this crucial stage of their careers." The Alfred P. Sloan Foundation is a philanthropic, not-for-profit grant making institution based in New York City. Established in 1934 by Alfred Pritchard Sloan Jr., then-president and chief executive officer of the General Motors Corporation, the Foundation makes grants in support of original research and education in science, technology, engineering, mathematics, and economics.
News Article | November 30, 2016
LONDON, Nov. 30, 2016 /PRNewswire/ -- Robert A. Figlin, MD, FACP, joins the 4Dx board on December 1st. Dr Figlin is Deputy Director of the Integrated Oncology Service Line. He also serves as the Deputy Director at the Samuel Oschin Comprehensive Cancer Institute, part of the world-renowned Cedars-Sinai Medical Center in Los Angeles and is Director of the Hematology Oncology Division at the institute, where he is in charge of integrating research and clinical strategies across all the Cedars-Sinai campuses. Since his arrival at Cedars- Sinai, he established the Experimental Therapeutics Program and successfully recruited clinical research staff in critical specialty areas such as breast cancer, bone marrow transplant, gastrointestinal oncology, genitourinary oncology, survivorship, and cancer biology. Dr Figlin says, "4Dx has developed some of the most promising and exciting technology I've ever seen in the fight against disease. It will be a privilege to be able to use my medical and business experience to assist the company through this phase of its growth." Dr Figlin co-founded Agensys - an early stage biotechnology company focussed on developing novel therapies for cancer. The company has since been sold to Astellas Pharmaceuticals as part of a nine-figure deal. 4Dx founder and chair, Andreas Fouras, says, "Bob Figlin brings unparalleled experience and expertise in cancer therapies to 4Dx, where enhanced cancer treatment is among our first priorities. Bob brings a vast medical knowledge and adds enormous capacity to our board's business decision making capacity." Lung cancer is the biggest killer of all cancers and the current standard treatments of chemotherapy and radiotherapy have devastating effects on the lungs. 4Dx technology is non-invasive and will positively impact the way medical professionals are able to diagnose, and treat their patients. "4Dx is undergoing significant acceleration and is thrilled to have a clinician, researcher and entrepreneurial thinker in Bob Figlan join our team." "This revolutionary technology and the development of unique software to generate moving, ultra-high-resolution images of motion and airflow in lung tissue enables clinicians to view and measure abnormal lung function at the earliest stages of disease in a way that has not been possible before now." As well as their association with Cedars- Sinai, 4Dx has also created partnerships with other leading hospitals such as the Cleveland Clinic and the Children's Hospital Los Angeles in the US, and The Alfred and Peter Mac in Australia. About 4Dx: 4Dx is a software company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders, including, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The unique 4Dx technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. Our Software-as-a-Service scans deliver much more complete results, showing the subtlest variations in lung function down to the finest details, using lower levels of radiation than traditional methods. Respiratory diagnosis is a $25 billion p.a global industry that 4Dx aims to disrupt and grow through technology that provides clinicians with greater insights into diseases of the lung. 4Dx will bring about a step change in lung health by providing better information to doctors and patients.